Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Bone Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              BELGIUM Belgium

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ASCO 2020

              Participation Not Confirmed

              Update your events

              Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates

              Contact the Supplier

              Lead Product(s): Hyaluronic Acid

              Therapeutic Area: Musculoskeletal

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 23, 2020

              Details:

              Two studies are the pivotal JTA-004 Ph III clinical study targeting osteoarthritic knee pain and Ph IIb study of its allogeneic cell therapy product, ALLOB, in difficult tibial fractures.

              PharmaCompass__DigitalAd